Brazil's atrial fibrillation market expected to grow at 31% pa over next five years
The Brazilian market for atrial fibrillation will increase at a rate of 31% per year from 2011 to 2016, according to advisory firm Decision Resources new Emerging Markets report titled Atrial Fibrillation in Brazil, which finds that this dramatic growth will be fueled by an increased drug-treated population and the proliferation of treatment alternatives for stroke prophylaxis in atrial fibrillation.
According to surveyed Brazilian cardiologists, new branded oral anticoagulants, such as Boehringer Ingelheim’s Pradaxa (dabigatran) and Bayer (BAYN: DE)/Janssen’s Xarelto (rivaroxaban), will capture 79% of Brazil’s atrial fibrillation drug market in 2016, owing to their relatively high prices and superior clinical profiles over warfarin (Bristol-Myers Squibb’s Coumadin, generics) and aspirin.
Eliquis set to be market leader post launch
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze